-
Clinical Trials & Development1 week agoAbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed...
-
Clinical Trials & Development1 week agoAbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa
NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and...
-
Clinical Trials & Development1 week agoSTAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
-
Clinical Trials & Development1 week agoSTAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations
AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.
-
Clinical Trials & Development1 week agoComplex Innovative Trial Design Meeting Program
As displayed in the Federal Register notice on August 1, 2018, FDA is conducting a Complex Innovative Designs (CID) Meeting Program to support the goal of...
-
Clinical Trials & Development1 week agoSmall Uncontrolled Trial Links Oxaloacetate to Improved Cognition After Breast Cancer
A small, uncontrolled phase II trial associated eight weeks of oxaloacetate with improved cognition, fatigue and physical functioning in 16 breast cancer survivors who completed treatment.
-
Clinical Trials & Development1 week agoRoivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a...
-
Clinical Trials & Development1 week agoClinical trial setup times fall sharply in UK
Reforms to the regulatory framework for clinical research in the UK are starting to deliver, with delivery times down 35%, according to new data.
-
Clinical Trials & Development1 week agoMost treated GI cancer patients used emergency care in retrospective cohort
A retrospective cohort of 2,278 chemotherapy-treated gastrointestinal cancer patients found that 88.1% visited an emergency department and 86.5% were admitted to a hospital during their first...
-
Clinical Trials & Development1 week agoField trial links bacterial co-inoculation to mungbean yield gains
A randomized block-design field experiment found that co-inoculating mungbean with Bradyrhizobium and selected PGPR improved yield, grain protein and rhizosphere biological measures under the tested conditions.
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
